A standard cardiac workup captures a few hours of heart activity. Arrhythmias are rarely polite enough to appear on schedule.
Kardi Ai, a Czech medtech startup, has raised €5.3M in a Series A led by German healthtech fund Callisto Health. Česká spořitelna and Slovenská sporiteľňa joined through Seed Starter, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.
A strap, an app and a model
The product pairs a fitness-style chest strap with an ECG sensor, a mobile app and AI analysis of the recordings. Patients wear it through ordinary days, producing a far longer trace than a clinic visit allows.
The system does not issue diagnoses. It supports clinical decisions by surfacing patterns a physician can act on, which keeps the regulatory burden lighter than a diagnostic claim would carry.
In the Czech Republic the company works with more than 70 hospitals and over 20 corporate benefit partners, and says its technology has been used by more than 6,000 people. It reports suspected arrhythmias in roughly a quarter of users, including more than 500 findings classed as critical.
From detection to prediction
Chief executive Vlastimil Hrabal, who co-founded the company, describes the next step as identifying elevated risk before an arrhythmia appears. That means predictive models across repeat measurements, work still in development and still needing clinical validation and regulatory clearance.
Kardi Ai has moved into Slovakia with more than 20 physicians, mostly cardiologists, and operates in Poland, Romania and Bulgaria. Germany is next after pilot projects, and it holds approvals supporting entries into India and the United Arab Emirates while completing device approval in Singapore.
The company frames the addressable base as nearly two billion people across markets it serves or is preparing to enter. Germany is the near-term test of whether the model travels.
